{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:24:21Z","timestamp":1784013861679,"version":"3.55.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.mayocp.2012.02.021","type":"journal-article","created":{"date-parts":[[2012,7,3]],"date-time":"2012-07-03T14:19:01Z","timestamp":1341325141000},"page":"779-790","source":"Crossref","is-referenced-by-count":52,"title":["Long-term Medical Management of the Liver Transplant Recipient: What the Primary Care Physician Needs to Know"],"prefix":"10.1016","volume":"87","author":[{"given":"Siddharth","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kymberly D.","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mayocp.2012.02.021_bib2","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1600-6143.2010.03126.x","article-title":"Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study","volume":"10","author":"Watt","year":"2010","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.021_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/lt.22198","article-title":"Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events","volume":"17","author":"Laish","year":"2011","journal-title":"Liver Transpl"},{"issue":"8","key":"10.1016\/j.mayocp.2012.02.021_bib4","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/lt.21126","article-title":"Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events","volume":"13","author":"Laryea","year":"2007","journal-title":"Liver Transpl"},{"issue":"11","key":"10.1016\/j.mayocp.2012.02.021_bib5","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/lt.21588","article-title":"Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression","volume":"14","author":"Bianchi","year":"2008","journal-title":"Liver Transpl"},{"issue":"3","key":"10.1016\/j.mayocp.2012.02.021_bib6","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of the metabolic syndrome among US adults; findings from the Third National Health and Nutrition Examination Survey","volume":"287","author":"Ford","year":"2002","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.mayocp.2012.02.021_bib7","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/lt.21786","article-title":"Long-term management after liver transplantation: primary care physician versus hepatologist","volume":"15","author":"Heller","year":"2009","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.021_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/lt.500030101","article-title":"Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506)","volume":"3","author":"Canzanello","year":"1997","journal-title":"Liver Transpl Surg"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.021_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1161\/01.HYP.32.1.46","article-title":"Hepatic denervation chronically elevates arterial pressure in Wistar-Kyoto rats","volume":"32","author":"Carlson","year":"1998","journal-title":"Hypertension"},{"issue":"19","key":"10.1016\/j.mayocp.2012.02.021_bib10","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.mayocp.2012.02.021_bib11","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/01.tp.0000262706.28513.6a","article-title":"Reducing the risks of cardiovascular disease in liver allograft recipients","volume":"83","author":"Mells","year":"2007","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.mayocp.2012.02.021_bib12","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/01.TP.0000116418.78963.DC","article-title":"Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation","volume":"77","author":"Neal","year":"2004","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.mayocp.2012.02.021_bib13","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1440-1746.2008.05461.x","article-title":"Liver disease and the renin-angiotensin system: recent discoveries and clinical implications","volume":"23","author":"Lubel","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.mayocp.2012.02.021_bib14","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/lt.21442","article-title":"Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial","volume":"14","author":"Galioto","year":"2008","journal-title":"Liver Transpl"},{"issue":"9","key":"10.1016\/j.mayocp.2012.02.021_bib15","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/j.1600-6143.2009.02733.x","article-title":"Long-term management of the liver transplant patient: recommendations for the primary care doctor","volume":"9","author":"McGuire","year":"2009","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.021_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.TP.0000100685.70064.90","article-title":"Is there disparity between risk and incidence of cardiovascular disease after liver transplant?","volume":"77","author":"Neal","year":"2004","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.021_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.510250132","article-title":"Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss","volume":"25","author":"Stegall","year":"1997","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.mayocp.2012.02.021_bib18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1053\/jlts.2001.24637","article-title":"Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight","volume":"7","author":"Neal","year":"2001","journal-title":"Liver Transpl"},{"issue":"9256","key":"10.1016\/j.mayocp.2012.02.021_bib19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(00)04055-1","article-title":"Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study","volume":"357","author":"Schlitt","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.mayocp.2012.02.021_bib20","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/01.ASN.0000113248.59077.76","article-title":"Rapamune Maintenance Regimen Trial","volume":"15","author":"Kreis","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.mayocp.2012.02.021_bib21","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1097\/TP.0b013e31816f1b7c","article-title":"Predictive factors for posttransplant diabetes mellitus within one-year of liver transplantation","volume":"85","author":"Oufroukhi","year":"2008","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.mayocp.2012.02.021_bib22","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/01.tp.0000250361.60415.96","article-title":"Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up","volume":"82","author":"Moon","year":"2006","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.mayocp.2012.02.021_bib23","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1097\/TP.0b013e3181d2fec1","article-title":"Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network\/United Network for Organ Sharing database","volume":"89","author":"Kuo","year":"2010","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.021_bib24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0168-8278(96)80329-1","article-title":"Diabetes mellitus after liver transplantation: prevalence and predictive factors","volume":"25","author":"Navasa","year":"1996","journal-title":"J Hepatol"},{"issue":"6, suppl","key":"10.1016\/j.mayocp.2012.02.021_bib25","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.transproceed.2009.06.159","article-title":"Mammalian target of rapamycin and diabetes: what does the current evidence tell us?","volume":"41","author":"Vodenik","year":"2009","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.mayocp.2012.02.021_bib26","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/jhep.2001.29134","article-title":"Outcome of liver transplantation in patients with diabetes mellitus: a case-control study","volume":"34","author":"John","year":"2001","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.mayocp.2012.02.021_bib27","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1600-6143.2009.02642.x","article-title":"Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C","volume":"9","author":"Veldt","year":"2009","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.mayocp.2012.02.021_bib28","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/lt.21524","article-title":"The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation","volume":"14","author":"Hanouneh","year":"2008","journal-title":"Liver Transpl"},{"issue":"3","key":"10.1016\/j.mayocp.2012.02.021_bib29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1399-0012.2005.00359.x","article-title":"Guidelines for the treatment and management of new-onset diabetes after transplantation","volume":"19","author":"Wilkinson","year":"2005","journal-title":"Clin Transplant"},{"issue":"11","key":"10.1016\/j.mayocp.2012.02.021_bib30","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1210\/jc.2011-0657","article-title":"Approach to the patient with new-onset diabetes after transplant (NODAT)","volume":"96","author":"Lane","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2012.02.021_bib31","first-page":"S11","article-title":"Standards of medical care in diabetes\u20142011","volume":"34","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.021_bib32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2010.01.040","article-title":"Metabolic syndrome and liver transplantation: a review and guide to management","volume":"53","author":"Watt","year":"2010","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.021_bib33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis","volume":"35","author":"Boettcher","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.021_bib34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1432-2277.2000.tb01040.x","article-title":"Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients","volume":"13","author":"Emre","year":"2000","journal-title":"Transpl Int"},{"issue":"5","key":"10.1016\/j.mayocp.2012.02.021_bib35","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/lt.21116","article-title":"Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients","volume":"13","author":"Morard","year":"2007","journal-title":"Liver Transpl"},{"issue":"3","key":"10.1016\/j.mayocp.2012.02.021_bib36","first-page":"323","article-title":"Long-term medical complications and quality of life in adult recipients surviving 10 years or more after liver transplantation","volume":"68","author":"Ciccarelli","year":"2005","journal-title":"Acta Gastroenterol Belg"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.021_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1399-0012.2007.00780.x","article-title":"Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients","volume":"22","author":"Martin","year":"2008","journal-title":"Clin Transplant"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.021_bib38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003495-200363040-00003","article-title":"Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients","volume":"63","author":"Asberg","year":"2003","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.mayocp.2012.02.021_bib39","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/lt.21710","article-title":"Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia","volume":"15","author":"Almutairi","year":"2009","journal-title":"Liver Transpl"},{"issue":"6","key":"10.1016\/j.mayocp.2012.02.021_bib40","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2146\/ajhp060164","article-title":"Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia","volume":"64","author":"McKenney","year":"2007","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.021_bib41","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/hep.21645","article-title":"Omega-3 fatty acids and liver disease","volume":"45","author":"Lee","year":"2007","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.mayocp.2012.02.021_bib42","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2012.02.021_bib43","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1681\/ASN.2007040394","article-title":"Chronic kidney disease after nonrenal solid-organ transplantation","volume":"18","author":"Bloom","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.mayocp.2012.02.021_bib44","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/lt.20445","article-title":"Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation","volume":"11","author":"Campbell","year":"2005","journal-title":"Liver Transpl"},{"issue":"suppl 2","key":"10.1016\/j.mayocp.2012.02.021_bib45","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/lt.20617","article-title":"Impact of pretransplant renal failure: when is listing for kidney-liver indicated?","volume":"11","author":"Davis","year":"2005","journal-title":"Liver Transpl"},{"issue":"24","key":"10.1016\/j.mayocp.2012.02.021_bib46","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy","volume":"349","author":"Nankivell","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2012.02.021_bib47","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/ndt\/gfh462","article-title":"Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy","volume":"19","author":"Artz","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.021_bib48","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/lt.20926","article-title":"Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension","volume":"13","author":"Orlando","year":"2007","journal-title":"Liver Transpl"},{"issue":"suppl 3","key":"10.1016\/j.mayocp.2012.02.021_bib49","first-page":"S84","article-title":"The impact of timing in sirolimus conversion for renal insufficiency in liver transplant recipients [abstract]","volume":"17","author":"McKenna","year":"2011","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.021_bib50","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/hep.23835","article-title":"Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis","volume":"52","author":"Asrani","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.mayocp.2012.02.021_bib51","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/00007890-200203270-00012","article-title":"Cardiovascular morbidity and mortality after orthotopic liver transplantation","volume":"73","author":"Johnston","year":"2002","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.mayocp.2012.02.021_bib52","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1053\/j.gastro.2009.08.070","article-title":"Long-term probability of and mortality from de novo malignancy after liver transplantation","volume":"137","author":"Watt","year":"2009","journal-title":"Gastroenterology"},{"issue":"11, suppl 1","key":"10.1016\/j.mayocp.2012.02.021_bib53","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1053\/jlts.2001.28645","article-title":"De novo malignancies after liver transplantation: a major cause of late death","volume":"7","author":"Fung","year":"2001","journal-title":"Liver Transpl"},{"issue":"10","key":"10.1016\/j.mayocp.2012.02.021_bib54","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/lt.21475","article-title":"Risk of malignant neoplasms after liver transplantation: a population-based study","volume":"14","author":"Aberg","year":"2008","journal-title":"Liver Transpl"},{"issue":"9","key":"10.1016\/j.mayocp.2012.02.021_bib55","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1478-3231.2010.02303.x","article-title":"Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review","volume":"30","author":"Chak","year":"2010","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.mayocp.2012.02.021_bib56","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.transproceed.2006.08.065","article-title":"Incidence of de novo nonmelanoma skin tumors after liver transplantation for alcoholic and nonalcoholic liver diseases","volume":"38","author":"Jim\u00e9nez-Romero","year":"2006","journal-title":"Transplant Proc"},{"issue":"17","key":"10.1016\/j.mayocp.2012.02.021_bib57","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation","volume":"348","author":"Euvrard","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.021_bib58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jhep.2005.10.008","article-title":"Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation?","volume":"44","author":"Aucejo","year":"2006","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.mayocp.2012.02.021_bib59","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MOT.0b013e3283465715","article-title":"Posttransplant lymphoproliferative disease following liver transplantation","volume":"16","author":"Kamdar","year":"2011","journal-title":"Curr Opin Organ Transplant"},{"issue":"35","key":"10.1016\/j.mayocp.2012.02.021_bib60","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.3748\/wjg.v16.i35.4377","article-title":"Liver transplantation for alcoholic liver disease","volume":"16","author":"Varma","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.mayocp.2012.02.021_bib61","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ibd.21692","article-title":"Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis","volume":"18","author":"Hanouneh","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.mayocp.2012.02.021_bib62","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1111\/j.1600-6143.2009.02766.x","article-title":"Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients","volume":"9","author":"Finkenstedt","year":"2009","journal-title":"Am J Transplant"},{"issue":"9253","key":"10.1016\/j.mayocp.2012.02.021_bib63","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(00)03641-2","article-title":"Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study","volume":"357","author":"Leidig-Bruckner","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.021_bib64","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.21805","article-title":"Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors","volume":"46","author":"Guichelaar","year":"2007","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.mayocp.2012.02.021_bib65","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1432-2277.2009.00976.x","article-title":"Effect of bisphosphonates on bone mineral density in liver transplant patients: a meta-analysis and systematic review of randomized controlled trials","volume":"23","author":"Kasturi","year":"2010","journal-title":"Transpl Int"},{"issue":"10","key":"10.1016\/j.mayocp.2012.02.021_bib66","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/00007890-200111270-00021","article-title":"Hyperuricemia, gout, and renal function after liver transplantation","volume":"72","author":"Neal","year":"2001","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.mayocp.2012.02.021_bib67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000064811","article-title":"Psychiatric and psychosocial outcome of orthotopic liver transplantation","volume":"71","author":"Rothenh\u00e4usler","year":"2002","journal-title":"Psychother Psychosom"},{"issue":"7","key":"10.1016\/j.mayocp.2012.02.021_bib68","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/j.1600-6143.2005.00969.x","article-title":"Reproduction and transplantation: report on the AST consensus conference on reproductive issues and transplantation","volume":"5","author":"McKay","year":"2005","journal-title":"Am J Transpl"},{"issue":"9","key":"10.1016\/j.mayocp.2012.02.021_bib69","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/j.1478-3231.2008.01871.x","article-title":"Pregnancy and liver transplantation","volume":"28","author":"Surti","year":"2008","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.021_bib70","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0029-7844(03)00369-7","article-title":"Pregnancy outcome in liver transplant recipients","volume":"102","author":"Nagy","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.mayocp.2012.02.021_bib71","first-page":"29","article-title":"Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation","author":"Coscia","year":"2007","journal-title":"Clin Transpl"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2012.02.021_bib72","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1111\/j.1440-1797.2006.00735.x","article-title":"The CARI guidelines: calcineurin inhibitors in renal transplantation; pregnancy, lactation and calcineurin inhibitors","volume":"12","author":"Grimer","year":"2007","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.021_bib73","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/lt.22441","article-title":"Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis","volume":"18","author":"Liang","year":"2012","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.021_bib74","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ncpgasthep1312","article-title":"Orthotopic liver transplantation and what to do during follow-up: recommendations for the practitioner","volume":"6","author":"Benten","year":"2009","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"10, suppl 1","key":"10.1016\/j.mayocp.2012.02.021_bib75","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1053\/jlts.2002.35781","article-title":"Natural history of recurrent hepatitis C","volume":"8","author":"Berenguer","year":"2002","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.021_bib76","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1053\/jlts.2001.23011","article-title":"Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis","volume":"7","author":"Contos","year":"2001","journal-title":"Liver Transpl"},{"issue":"7","key":"10.1016\/j.mayocp.2012.02.021_bib77","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/jlts.2001.25453","article-title":"Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease","volume":"7","author":"Charlton","year":"2001","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1016\/j.mayocp.2012.02.021_bib78","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/lt.21028","article-title":"Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation?","volume":"13","author":"Vivarelli","year":"2007","journal-title":"Liver Transpl"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619612004703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619612004703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T10:56:30Z","timestamp":1542884190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619612004703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":77,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0025619612004703"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2012.02.021","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}